J Fam Plann Reprod Health Care. 2004 Jul;30(3):163-5
An observational study of Yasmin in the management of women with
polycystic ovary syndrome. Department of Reproductive Medicine, Leeds General Infirmary, Leeds, UK. Polycystic ovary syndrome (PCOS) is the commonest endocrine disturbance
affecting women in the reproductive age group and encompasses signs of
hyperandrogenism, menstrual cycle disturbances and obesity. Some of the symptoms
of PCOS may be ameliorated by the combined oral contraceptive pill (COCP).
A pilot observational study was carried out in a university teaching hospital
setting to determine whether the clinical and biochemical features of PCOS are
ameliorated by a new COCP, Yasmin, which contains a new progestogen,
drosperinone. Treatment with Yasmin was given for 6 months to 17 patients. Thirteen patients (76%) completed 6 months of therapy. Good cycle control was
achieved in all patients. Percentage body fat increased, with no overall change
in body mass index. Fasting insulin and triglyceride concentrations rose
significantly. Serum total testosterone concentrations fell with a concomitant
rise in sex hormone binding globulin levels. Hirsutism scores did not change
significantly in the 12 women who were clinically hirsute. There was, however, a
significant improvement in the acne scores. Four of the 17 patients dropped out
of the trial between Cycles 3 and 5 due to side effects. Yasmin provides good cycle control for women with PCOS, with an improvement
in acne over 6 months but not in other symptoms of the syndrome.
Background:
Methods:
Results:
Conclusions:
